secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095073
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026
------------------------------------------------------------------------------

- Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.
- Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.
- ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.
- ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.
- ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/0000950170-24-095073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/annx-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer